Physician profile
Ami R Patel
NPI 1326123423
$4,782.23
in general payments reported to CMS, 2019-2025
29 companies · $711 in 2025
The $711 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $287 · 2021: $616 · 2022: $966 · 2023: $841 · 2024: $593 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.74 |
| Education | $125.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $862.78 | 2019-2025 | Lokelma, Farxiga |
| W. L. Gore & Associates, INC. | $397.43 | 2021-2023 | Gore Acuseal Vascular Graft |
| Otsuka America Pharmaceutical, INC. | $335.68 | 2019-2025 | Jynarque |
| Amgen INC. | $329.37 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Akebia Therapeutics INC | $324.74 | 2019-2024 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $307.06 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $287.96 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $216.20 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $209.38 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $195.73 | 2021-2024 | Lupkynis |
| Vifor Pharma, INC. | $187.32 | 2019-2022 | |
| Nxstage Medical, INC. | $181.30 | 2020-2025 | Nxstage System One, Liberty Select Cycler |
| Calliditas Therapeutics US INC. | $173.54 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $132.94 | 2020-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $99.95 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $95.08 | 2022-2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $70.17 | 2021-2023 | Hetlioz, Fanapt |
| Ardelyx, INC. | $64.95 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.17 | 2025 | Voyxact |
| Alexion Pharmaceuticals, INC. | $48.69 | 2019-2021 | |
| Daiichi Sankyo INC. | $45.82 | 2021-2024 | Injectafer |
| Travere Therapeutics, INC. | $35.72 | 2023 | |
| Genentech USA, INC. | $24.94 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.32 | 2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $19.21 | 2019 | |
| Novo Nordisk INC | $18.39 | 2025 | Wegovy |
| Lilly USA, LLC | $17.10 | 2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $15.59 | 2025 | Tryvio |
| Scpharmaceuticals INC. | $13.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.